Investment
Features
FeesSafety
Academy
More
Pluang+

Calix rated Buy at $34.81 with 33% upside on software growth and cost cuts

Analyst Insights
06 Oct 2026
Seeking Alpha
View Source
Bullish
Calix rated Buy at $34.81 with 33% upside on software growth and cost cuts

Calix is rated a Buy at around $34.81 due to expected growth in software and managed-service revenues, along with expanding customer relationships. The company's completed cloud migration has improved gross margins and lowered costs, strengthening its earnings outlook. The valuation at 20.2 times FY2026 adjusted earnings is attractive, with a target price of about $46.33 by FY2028, implying a 33% upside based on 16% annual EPS growth. Continued growth in software and service revenues, cost recovery, and better cash flow are key to realizing this potential.

Calix's buy case is outlined alongside Pluang's Technology sector data for context. Of 150 priced US Technology stocks on Pluang, 108 advanced and 36 declined today. Notable movers include Crowdstrike Holdings Inc at USD 277.00 with a 1.59% increase and a typical hold time of 97 days, as of Oct 06, 2026 16:32 WIB.

More News

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...

Analyst Insights
Neutral
3 hours ago
IceCure Medical adds Legacy Health to U.S. study on cryoablation for low-risk breast cancer

IceCure Medical adds Legacy Health to U.S. study on cryoablation for low-risk breast cancer

IceCure Medical has expanded its U.S. clinical network for the ChoICE Study by adding Legacy Health in Oregon as a new site. The study evaluates the safety and effectiveness of ProSense® cryoablation, a minimally invasive treatment for low-risk breas...

Market News
Bullish
4 hours ago
Palantir's stock jumps 60% in Q3, its best quarter in over a year, but high valuation demands flawless growth.

Palantir's stock jumps 60% in Q3, its best quarter in over a year, but high valuation demands flawless growth.

Palantir Technologies saw its stock rise 60.3% in the third quarter, marking its strongest quarterly gain since mid-2025, driven by a 93% revenue increase to $1.935 billion and a 149% jump in U.S. commercial revenue. Despite this surge, Palantir is o...

Company Fundamentals
Bullish
4 hours ago
Nike shares hit worst year but long-term investors see buying opportunity amid turnaround hopes

Nike shares hit worst year but long-term investors see buying opportunity amid turnaround hopes

Nike shares are performing poorly this year, reflecting investor skepticism due to the company's struggling operating results. Despite the negative sentiment, analyst Justin Purohit believes that long-term investors could benefit from holding onto or...

Analyst Insights
Bullish
4 hours ago
Dogecoin offers no staking yield; any DOGE yield comes from lending with risks and tax implications.

Dogecoin offers no staking yield; any DOGE yield comes from lending with risks and tax implications.

Dogecoin's protocol does not support staking, so any yield offered on DOGE holdings comes from third-party lending services, not from the blockchain itself. Dogecoin operates on proof of work, issuing about 3.2% new supply annually, which dilutes hol...

Protocol Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App